Aldeyra Therapeutics Inc. (ALDX)
NASDAQ: ALDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $50.70M
- EPS (TTM)
- -$0.31
- Dividend yield
- None
- 52-week range
- 0.527 – 5.93
- Day range
- 0.6589 – 0.8849
- Volume / Avg
- 2.47M / 1.16M
- Beta
- —
- Shares outstanding
- 60.36M
52-week range
ALDX stock today
Aldeyra Therapeutics (ALDX) closed at $0.84 on Nov 20, up 16.39% (+$0.1183), versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 2.47M shares, a sign of unusually heavy trading. Shares are 85.8% below their 52-week high of $5.93, set on Jan 30, 2026 and 59.4% above the 52-week low of $0.527, near the bottom of the past year's range.
ALDX is down 83.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 83.1%. Aldeyra Therapeutics has posted a net loss over the last twelve months (EPS of -$0.31), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Aldeyra Therapeutics
Company profileAldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Todd C. Brady M.D., Ph.D.
- Headquarters
- Lexington, MA
- Employees
- 6
- IPO year
- 2014
- Website
- aldeyra.com
Financial highlights
Full financialsAldeyra Therapeutics reported a net loss of $33.8 million, compared with a loss of $55.9 million a year earlier. Diluted earnings per share came in at -$0.56.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-33.85M | $-55.85M | $-37.54M | $-62.02M | $-57.78M |
| EPS (diluted) | $-0.56 | $-0.94 | $-0.64 | $-1.06 | $-1.07 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$6.60+685.71%
- Strong buy 1
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.06 vs $-0.11
- Surprise
- +45.45%
ALDX news
All ALDX news- Aldeyra Therapeutics, Inc. Receives Nasdaq Notice Regarding $1.00 Minimum Bid Price RequirementNasdaq
- RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekNasdaqRARE, AMRN, CORT, ALDX
- Here's Why You Should Add ANRO Stock to Your Portfolio NowNasdaqANRO, AMRN, CORT, ALDX
- Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary GoalNasdaqSNDX, AMRN, CORT, ALDX
- Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyNasdaqAMRN, CORT, ALDX, PRME
- PMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowNasdaqPMVP, AMRN, CORT, ALDX
- argenx Meets Primary Endpoint in Phase II Celiac Disease StudyNasdaqARGX, ALNY, AMRN, ALDX
- EDIT Set to Begin First-in-Human Study in HypercholesterolemiaNasdaqEDIT, ALNY, AMRN, ALDX
Aldeyra Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLNNClene Inc. | 3.52 | +0.57% | $50.69M | vs ALDX |
| ACRVAcrivon Therapeutics Inc. | 1.15 | -17.86% | $49.35M | vs ALDX |
| LFVNLifevantage Corporation | 4.15 | -15.13% | $52.63M | vs ALDX |
| XBITXBiotech Inc. | 1.73 | +2.98% | $52.74M | vs ALDX |
| CTORCitius Oncology Inc. | 0.5035 | -10.95% | $53.25M | vs ALDX |
| HRTXHeron Therapeutics Inc. | 0.2525 | -4.39% | $48.04M | vs ALDX |
| XLOXilio Therapeutics Inc. | 7.56 | -1.11% | $53.40M | vs ALDX |
| RFLRafael Holdings Inc. Class B | 0.9197 | +2.19% | $47.99M | vs ALDX |
Indexes, lists and sector
Aldeyra Therapeutics stock FAQ
What is Aldeyra Therapeutics's stock price today?
ALDX last traded at $0.84 as of Nov 20, 4:00 PM EST, up 16.39% on the day. Prices are delayed at least 15 minutes.
Who is Aldeyra Therapeutics's CEO?
Dr. Todd C. Brady M.D., Ph.D. is the chief executive officer of Aldeyra Therapeutics Inc., which has about 6 employees.
What is the ALDX 52-week high?
The 52-week high for ALDX is $5.93 and the 52-week low is $0.527. The stock is currently 85.8% below its high.